Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer

Overview of attention for article published in Frontiers in oncology, February 2024

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,666 followers.

RT @FrontOncology: New research: Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of…

13 Feb 2024

Reply Repost Favourite

New research: Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer: Objective Incompletely resected epithelial ovarian cancer represents a… https://t.co/l

13 Feb 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.